Follow
Yi-long Wu
Yi-long Wu
Professor of Oncology, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital
Verified email at gdph.org.cn
Title
Cited by
Cited by
Year
Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma
TS Mok, YL Wu, S Thongprasert, CH Yang, DT Chu, N Saijo, ...
New England Journal of Medicine 361 (10), 947-957, 2009
94502009
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang, S Zhang, J Wang, ...
The lancet oncology 12 (8), 735-742, 2011
47202011
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ...
New England Journal of Medicine 368 (25), 2385-2394, 2013
37482013
First-line crizotinib versus chemotherapy in ALK-positive lung cancer
BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ...
N Engl j Med 371, 2167-2177, 2014
32412014
The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer
P Goldstraw, K Chansky, J Crowley, R Rami-Porta, H Asamura, ...
Journal of Thoracic Oncology 11 (1), 39-51, 2016
29872016
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
TS Mok, YL Wu, MJ Ahn, MC Garassino, HR Kim, SS Ramalingam, ...
New England Journal of Medicine 376 (7), 629-640, 2017
28412017
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro, ...
The lancet 393 (10183), 1819-1830, 2019
2294*2019
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open …
YL Wu, C Zhou, CP Hu, J Feng, S Lu, Y Huang, W Li, M Hou, JH Shi, ...
The lancet oncology 15 (2), 213-222, 2014
21872014
Lung cancer: current therapies and new targeted treatments
FR Hirsch, GV Scagliotti, JL Mulshine, R Kwon, WJ Curran, YL Wu, ...
The Lancet 389 (10066), 299-311, 2017
21492017
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M Krzakowski, E Laack, ...
The Lancet 374 (9699), 1432-1440, 2009
1765*2009
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically …
M Fukuoka, YL Wu, S Thongprasert, P Sunpaweravong, SS Leong, ...
Journal of clinical oncology 29 (21), 2866-2874, 2011
17512011
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
ES Kim, V Hirsh, T Mok, MA Socinski, R Gervais, YL Wu, LY Li, ...
The Lancet 372 (9652), 1809-1818, 2008
17162008
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised …
JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ...
The lancet oncology 16 (2), 141-151, 2015
16772015
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC
AB Turke, K Zejnullahu, YL Wu, Y Song, D Dias-Santagata, E Lifshits, ...
Cancer cell 17 (1), 77-88, 2010
11602010
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
JC Soria, DSW Tan, R Chiari, YL Wu, L Paz-Ares, J Wolf, SL Geater, ...
The Lancet 389 (10072), 917-929, 2017
9952017
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
YL Wu, Y Cheng, X Zhou, KH Lee, K Nakagawa, S Niho, F Tsuji, R Linke, ...
The Lancet Oncology 18 (11), 1454-1466, 2017
9082017
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer
YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ...
New England Journal of Medicine 383 (18), 1711-1723, 2020
8202020
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3 …
JCH Yang, LV Sequist, SL Geater, CM Tsai, TSK Mok, M Schuler, ...
The lancet oncology 16 (7), 830-838, 2015
7892015
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open …
YL Wu, C Zhou, CK Liam, G Wu, X Liu, Z Zhong, S Lu, Y Cheng, B Han, ...
Annals of oncology 26 (9), 1883-1889, 2015
7112015
Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma
ZY Dong, WZ Zhong, XC Zhang, J Su, Z Xie, SY Liu, HY Tu, HJ Chen, ...
Clinical cancer research 23 (12), 3012-3024, 2017
6612017
The system can't perform the operation now. Try again later.
Articles 1–20